Nuvation Bio Q2 2026 earnings: IBTROZI lifts revenue to $31.7 million

Nuvation Bio (NYSE: NUVB) reported Q2 2026 revenue of $31.7 million, up from $4.8 million a year earlier, while GAAP basic and diluted loss per share was $0.18 versus $0.17. IBTROZI generated $23.2 million in net product revenue and grew 25% sequentially, helping narrow the operating loss, but financing-related expenses pushed the quarterly net loss to $62.8 million.

Core financial results

IBTROZI accounted for most of the revenue increase, although the year-over-year comparison reflects the timing of its commercial launch: Nuvation Bio began distributing the drug to U.S. customers in June 2025. Collaboration and license revenue also increased, primarily due to higher product-supply and royalty revenue.

The larger product contribution improved calculated gross profit and helped reduce the operating loss despite higher research and development and administrative spending. Net results moved in the opposite direction because other expenses increased materially.

Calculated gross profit subtracts cost of sales and cost of collaboration and license revenue from total revenue; the company did not present gross profit as a separate line item.

Commercial and pipeline performance

IBTROZI adoption

Nuvation Bio reported approximately 160 new IBTROZI patient starts during the quarter. About 85% were TKI-naïve patients, and starts in that treatment setting increased approximately 30% sequentially. Based on IQVIA claims from the first five months of 2026, the company said IBTROZI was the most prescribed ROS1 TKI for both first-line and overall new patient starts.

The FDA accepted a supplemental New Drug Application containing updated efficacy data for TKI-naïve and previously treated advanced ROS1-positive non-small cell lung cancer. The target action date is January 4, 2027. The submission included a median duration of response of 49.7 months and median progression-free survival of 49.6 months for TKI-naïve patients in TRUST-I, as well as a 19.4-month median duration of response for previously treated patients in TRUST-II.

Outside the U.S., the UK regulator validated the marketing authorization application submitted by partner Eisai. China and Japan collaboration agreements generated $2.1 million in quarterly royalty revenue, with taletrectinib included in China’s National Reimbursement Drug List from January 1, 2026.

Safusidenib development expands

Updated Phase 2 data reported in July showed a centrally assessed response rate of 51.9% in chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant glioma after a median follow-up of 38.8 months. Median progression-free survival had not been reached, and the 36-month progression-free survival rate was 79.1%. No new safety signals were identified.

Nuvation Bio subsequently expanded the program by initiating the Phase 3 G307 study outside the U.S. and the Phase 2 G209 study in U.S. patients whose disease progressed after prior vorasidenib treatment. The company had also acquired the Japanese rights to safusidenib in April, giving it full global development and commercialization rights.

IBTROZI gross profit narrowed the operating loss, but financing costs widened the net loss

IBTROZI supplied most of the quarter’s gross profit: product revenue was $23.2 million against $0.9 million of product cost of sales. By comparison, the $8.5 million of collaboration and license revenue carried $8.6 million of directly associated cost, providing little gross contribution during the quarter.

Operating expenses continued to rise. R&D expense increased mainly because clinical-trial costs were $4.6 million higher, partly offset by a $1.3 million decrease in personnel costs because the prior-year period included a one-time stock-based compensation charge. SG&A increased due to higher compensation, legal and professional fees, sales and marketing spending, and other expenses.

The expanding revenue base was sufficient to narrow the operating loss, but not the net loss. Nuvation Bio recorded a $9.5 million loss on debt extinguishment, while interest expense rose to $6.8 million from $0.4 million. As a result, the company moved from $4.6 million of net other income in Q2 2025 to $11.8 million of net other expense in Q2 2026.

Liquidity and balance sheet

Nuvation Bio held $661.0 million in cash, cash equivalents, and marketable securities as of June 30, 2026, consisting of $258.6 million in cash and equivalents and $402.4 million in marketable securities. That amount excluded another $36.5 million of net proceeds received in July through the exercise of the convertible-notes overallotment option.

The June balance sheet included $242.6 million of convertible debt, $47.2 million of long-term borrowings, and $5.9 million of short-term borrowings. Total liabilities increased to $490.6 million from $289.1 million at the end of 2025. Inventory rose to $19.9 million from $11.4 million, while accounts receivable increased to $27.8 million from $16.1 million.

Recent insider transactions

The supplied six-month insider summary classified 638,179 shares across nine transactions as purchases and 522,418 shares across six transactions as sales. That represented net purchases of 115,761 shares, equal to 0.2% of the 64.76 million insider shares reported as held.

The latest transaction records include exercises, sales, and one director purchase. The amounts below are reported transaction values; they should not be interpreted as evidence of insiders’ expectations for the company.

Risks investors should monitor

• Dependence on one commercial product: IBTROZI’s U.S. sales remain Nuvation Bio’s only source of product revenue. Patient starts, treatment duration, and continued first-line adoption therefore have an outsized effect on revenue growth.
• Ongoing losses and financing costs: Higher product revenue improved the operating result, but R&D and SG&A continued to rise, while debt-extinguishment and interest expenses widened the net loss. The expanded debt balance also adds financing obligations.
• Regulatory and clinical execution: The updated IBTROZI application remains subject to FDA review, while safusidenib’s broader opportunity depends on successful execution of new Phase 2 and Phase 3 studies. Earlier-stage results may change as data mature.
• IBTROZI safety considerations: The prescribing information includes warnings covering hepatotoxicity, interstitial lung disease or pneumonitis, and QTc prolongation. Safety management can affect treatment continuity and commercial adoption.

Summary

Nuvation Bio’s Q2 2026 results showed meaningful early revenue generation from IBTROZI, with product economics helping reduce the operating loss despite continued investment in commercialization and clinical development. Financing-related expenses prevented that improvement from reaching the bottom line. The main issues to monitor are the durability of IBTROZI patient growth, the January 2027 FDA decision, execution of the expanded safusidenib program, and how the company manages its larger debt-funded balance sheet.